Home › Compare › CHGCY vs GBDC

CHGCY vs GBDC: Dividend Comparison 2026

CHGCY yields 2.99% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHGCY wins by $385.05M in total portfolio value· pulled ahead in Year 7
10 years
CHGCY
CHGCY
● Live price
2.99%
Share price
$27.52
Annual div
$0.82
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$405.82M
Annual income
$381,294,826.82
Full CHGCY calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — CHGCY vs GBDC

📍 CHGCY pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHGCYGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHGCY + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CHGCY pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHGCY
Annual income on $10K today (after 15% tax)
$253.82/yr
After 10yr DRIP, annual income (after tax)
$324,100,602.80/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, CHGCY beats the other by $310,169,728.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHGCY + GBDC for your $10,000?

CHGCY: 50%GBDC: 50%
100% GBDC50/50100% CHGCY
Portfolio after 10yr
$213.30M
Annual income
$198,842,045.11/yr
Blended yield
93.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

CHGCY
No analyst data
Altman Z
22.5
Piotroski
6/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHGCY buys
0
GBDC buys
0
No recent congressional trades found for CHGCY or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHGCYGBDC
Forward yield2.99%11.85% ✓
Annual dividend / share$0.82$1.50 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100% ✓51.1%
Portfolio after 10y$405.82M ✓$20.78M
Annual income after 10y$381,294,826.82 ✓$16,389,263.41
Total dividends collected$404.01M ✓$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: CHGCY vs GBDC ($10,000, DRIP)

YearCHGCY PortfolioCHGCY Income/yrGBDC PortfolioGBDC Income/yrGap
1$11,297$597.22$12,490$1,790.28$1.2K → GBDC
2$13,349$1,261.10$16,522$3,157.73$3.2K → GBDC
3$17,069$2,785.33$23,578$5,898.68$6.5K → GBDC
4$24,921$6,656.96$37,115$11,886.75$12.2K → GBDC
5$44,832$18,166.72$66,136$26,423.57$21.3K → GBDC
6$109,057$61,087.10$137,257$66,491.44$28.2K → GBDC
7← crossover$394,447$277,755.94$341,734$194,868.54+$52.7K → CHGCY
8$2,299,836$1,877,777.60$1,050,788$685,133.02+$1.25M → CHGCY
9$22,925,198$20,464,373.86$4,099,314$2,974,971.01+$18.83M → CHGCY
10$405,824,789$381,294,826.82$20,775,530$16,389,263.41+$385.05M → CHGCY

CHGCY vs GBDC: Complete Analysis 2026

CHGCY — Stock

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Full CHGCY Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this CHGCY vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHGCY vs SCHDCHGCY vs JEPICHGCY vs OCHGCY vs KOCHGCY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.